This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Kay Alison Boardman: Innovator in Pharmaceutical Chemistry
Introduction
Kay Alison Boardman is a notable inventor based in Cheshire, GB. She has made significant contributions to the field of pharmaceutical chemistry, particularly through her innovative processes in drug preparation. Her work has implications for the development of new therapeutic agents.
Latest Patents
Kay Alison Boardman holds a patent for a process titled "Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline." This patent describes the processes for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline, salts thereof, and the intermediates used in the process. This innovation showcases her expertise in creating complex chemical compounds that can be utilized in various medical applications.
Career Highlights
Throughout her career, Kay has demonstrated a strong commitment to advancing pharmaceutical research. Her work at AstraZeneca AB has positioned her as a key player in the development of new medications. With a focus on innovative processes, she has contributed to the enhancement of drug formulation techniques.
Collaborations
Kay Alison Boardman has collaborated with esteemed colleagues, including Oliver Robert Cunningham and William Robert Fraser Goundry. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmaceutical chemistry.
Conclusion
Kay Alison Boardman is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug preparation processes. Her contributions continue to impact the industry positively, showcasing her dedication to innovation and collaboration.